Trial Outcomes & Findings for Penicillin and Metronidazole in Treatment of Peritonsillar Abscess (NCT NCT01255670)

NCT ID: NCT01255670

Last Updated: 2021-05-11

Results Overview

Number of participants with recurrence of peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

200 participants

Primary outcome timeframe

56 days

Results posted on

2021-05-11

Participant Flow

Participant milestones

Participant milestones
Measure
Penicillin and Metronidazole
After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Penicillin and Placebo
After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Overall Study
STARTED
100
100
Overall Study
COMPLETED
74
80
Overall Study
NOT COMPLETED
26
20

Reasons for withdrawal

Reasons for withdrawal
Measure
Penicillin and Metronidazole
After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Penicillin and Placebo
After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Overall Study
Adverse Event
10
10
Overall Study
Lost to Follow-up
16
10

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Penicillin and Metronidazole
n=100 Participants
After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Penicillin and Placebo
n=100 Participants
After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Total
n=200 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=100 Participants
0 Participants
n=100 Participants
0 Participants
n=200 Participants
Age, Categorical
Between 18 and 65 years
100 Participants
n=100 Participants
100 Participants
n=100 Participants
200 Participants
n=200 Participants
Age, Categorical
>=65 years
0 Participants
n=100 Participants
0 Participants
n=100 Participants
0 Participants
n=200 Participants
Sex: Female, Male
Female
47 Participants
n=100 Participants
44 Participants
n=100 Participants
91 Participants
n=200 Participants
Sex: Female, Male
Male
53 Participants
n=100 Participants
56 Participants
n=100 Participants
109 Participants
n=200 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
Finland
100 participants
n=100 Participants
100 participants
n=100 Participants
200 participants
n=200 Participants

PRIMARY outcome

Timeframe: 56 days

Number of participants with recurrence of peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo.

Outcome measures

Outcome measures
Measure
Penicillin and Metronidazole
n=100 Participants
After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Penicillin and Placebo
n=100 Participants
After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Number of Participants With Recurrence of Peritonsillar Abscess
10 Participants
10 Participants

SECONDARY outcome

Timeframe: 28 days

Number of participants recovering from peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo.

Outcome measures

Outcome measures
Measure
Penicillin and Metronidazole
n=84 Participants
After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Penicillin and Placebo
n=90 Participants
After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Number of Participants Recovering From Peritonsillar Abscess
74 Participants
80 Participants

Adverse Events

Penicillin and Metronidazole

Serious events: 0 serious events
Other events: 61 other events
Deaths: 0 deaths

Penicillin and Placebo

Serious events: 0 serious events
Other events: 51 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Penicillin and Metronidazole
n=100 participants at risk
After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Penicillin and Placebo
n=100 participants at risk
After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess. Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.
Gastrointestinal disorders
Nausea
10.0%
10/100
8.0%
8/100
Metabolism and nutrition disorders
Diarrhea
16.0%
16/100
10.0%
10/100
Nervous system disorders
Dizziness
12.0%
12/100
16.0%
16/100
Nervous system disorders
Headache
15.0%
15/100
12.0%
12/100
Skin and subcutaneous tissue disorders
Rash
8.0%
8/100
5.0%
5/100

Additional Information

Dr. Karin Blomgren

Helsinki University Central Hospital

Phone: +358504271579

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place